logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • gamma-Aminobutyric Acid A Receptor Positive Modulator class drugs

    FiltersReset Filters
    3 results

    • ambien

      (zolpidem tartrate)
      sanofi-aventis U.S. LLC
      Usage: AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep initiation. It effectively reduces sleep latency for up to 35 days, as demonstrated in controlled clinical studies lasting 4–5 weeks.

    • ambien

      (zolpidem tartrate)
      sanofi-aventis U.S. LLC
      Usage: AMBIEN CR (zolpidem tartrate extended-release tablets) is indicated for the short-term treatment of insomnia, particularly for difficulties with sleep onset and/or maintenance, as measured by wake time after sleep onset. Clinical trials supporting its efficacy lasted up to 24 weeks.

    • zolpidem tartrate

      (Zolpidem Tartrate)
      Lupin Pharmaceuticals, Inc.
      Usage: Zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia, specifically for difficulties with sleep onset and/or maintenance, as measured by wake time after sleep onset.